No profile data available.
Obsidian Therapeutics, Inc. (OBX) is a listed company, based in Cambridge, United States, with about 87 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$100.61 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $803.05 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer.
Obsidian Therapeutics reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$803.05 million as of October 9, 2026.